Review ArticleRenin-Angiotensin System, Hypertrophy and Gene Expression in Cardiac Myocytes☆
References (0)
Cited by (132)
The contribution of angiotensin peptides to cardiovascular neuroregulation in health and disease
2023, Angiotensin: From the Kidney to CoronavirusHematopoietic bone marrow renin-angiotensin system in health and disease
2023, Angiotensin: From the Kidney to CoronavirusPathophysiology of heart failure and an overview of therapies
2022, Cardiovascular PathologyFrom dissection of fibrotic pathways to assessment of drug interactions to reduce cardiac fibrosis and heart failure
2021, Current Research in Pharmacology and Drug DiscoveryPathophysiology of Atrial Fibrillation and Heart Failure: Dangerous Interactions
2019, Cardiology ClinicsSilencing of the Na <sup>+</sup> /H <sup>+</sup> exchanger 1(NHE-1) prevents cardiac structural and functional remodeling induced by angiotensin II
2019, Experimental and Molecular PathologyCitation Excerpt :This remodeling of the heart is characterized by an altered phenotype and constitutes an independent risk factor for morbidity and mortality that usually leads to heart failure (Levy et al., 1990; Katholi and Couri, 2011). In this sense, chronic activation of the renin angiotensin system (RAS) is responsible for several cardiac diseases, among which myocardial hypertrophy occupies an outstanding place (Lijnen and Petrov, 1999). It is well documented that angiotensin II (ANGII) activates NADPH-oxidase increasing reactive oxygen species (ROS) production that play a crucial role in the development of CH(Garrido and Griendling, 2009; Zhang et al., 2013).
- ☆
Please address all correspondence to: Prof Dr P. Lijnen, Hypertension Unit, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.